TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32593522
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of total polyphenols intake (319.9 mg/d)
Study: 32594377
Drug: Candida antigen
Normalized name: Candida antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candida antigen immunotherapy
Study: 32595770
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) at a dosage of 0.469 mg/kg/week for 12 months (group A)
Study: 32595770
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) for 6 months after 6 months untreated (group B)
Study: 32597029
Drug: Prophylactic rurioctocog
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly or less frequent)
Study: 32597029
Drug: Prophylactic rurioctocog
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly)
Study: 32597029
Drug: Prophylactic rurioctocog
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic rurioctocog alfa pegol (PK-tailored dose regimen)
Study: 32597419
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care radiotherapy ± chemotherapy
Study: 32598033
Drug: Statin medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medication
Study: 32598257
Drug: Selinexor 40
Normalized name: selinexor 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 40 mg plus mFOLFOX6
Study: 32598257
Drug: Selinexor 20
Normalized name: selinexor 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 20 mg plus mFOLFOX6
Study: 32600857
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention including fish oil intake (2g daily), dietary counselling, and unsupervised physical exercise twice weekly during the first three cycles of treatment
Study: 32601169
Drug: Caspofungin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin standard dosing
Study: 32602006
Drug: Kidney dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m²)
Study: 32602006
Drug: eGFR >
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR > 60 mL/min/1.73 m²
Study: 32604962
Drug: Abatacept +
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept + MTX with GC (≤10 mg/day)
Study: 32604962
Drug: Adalimumab +
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab + MTX with GC (≤10 mg/day)
Study: 32604962
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (abatacept and adalimumab)
Study: 32605050
Drug: Hypo-fractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-fractionated stereotactic radiation (HFSRT; 6 Gy × 5) plus pembrolizumab (100 or 200 mg, every 3 weeks) and bevacizumab (10 mg/kg, every 2 weeks)
Study: 32605888
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all MRI sequences
Study: 32606066
Drug: Consensus-based recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus-based recommendations for perioperative medication safety tailored to country income level
Study: 32606578
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 or 0.5 mg
Study: 32606899
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (LICUS, 3MHz, 0.132W/cm, 18,720 Joules)
Study: 32606899
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (LICUS)
Study: 32606903
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nalbuphine with 12.5 mg hyperbaric bupivacaine
Study: 32606903
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midazolam with 12.5 mg hyperbaric bupivacaine
Study: 32606903
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hyperbaric bupivacaine plus 0.5 mL saline (Control)
Study: 32606902
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under heat conditions
Study: 32606902
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under exercise conditions
Study: 32606902
Drug: Lidocaine topical
Normalized name: lidocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine topical system 1.8% under all conditions
Study: 32606956
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg 3 times per day)
Study: 32606956
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 mg 3 times per day)
Study: 32607502
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard of care (facilitating referral to a local substance use treatment clinic)
Study: 32607929
Drug: Simple Segmentation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Segmentation Tool (SST) administered by physicians and nurses
Study: 32611662
Drug: Adverse drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse drug reactions in patients with CKD
Study: 32611662
Drug: Specific pharmacologic
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific pharmacologic classes (antithrombotic agents)
Study: 32611728
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of alteplase
Study: 32611728
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of alteplase
Study: 32611729
Drug: Dynamic contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic contrast-enhanced MRI (DCE-MRI) before and 6 months after endovascular treatment
Study: 32611739
Drug: Therapy-naïve patients
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy-naïve patients receiving standard PIBD care with follow-up up to 20 years.
Study: 32613089
Drug: Low-dose lung
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lung irradiation (LD-RT) combined with pharmacological treatment
Study: 32613089
Drug: Low-dose lung
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lung irradiation (LD-RT)
Study: 32613402
Drug: Experimental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formula with high beta-PA (20-25%) from cow's milk fat and 0.5 g GOS/100 ml
Study: 32614327
Drug: Triaxial accelerometer
Normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triaxial accelerometer sensor placed on the anterior chest to monitor body positions 24-hours daily through a 4-week monitoring period.
Study: 36803645
Drug: Pyrotinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib monotherapy
Study: 32614702
Drug: Non-docetaxel-based chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-docetaxel-based chemotherapy
Study: 32614963
Drug: Treatment-free remission
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free remission (TFR) after stopping tyrosine kinase inhibitors (TKIs)
Study: 32615108
Drug: Avapritinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib (300 mg recommended phase 2 dose, administered orally once daily)
Study: 32615108
Drug: Avapritinib (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib (varied doses from 30 mg to 600 mg)
Study: 32615108
Drug: Avapritinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib (600 mg)
Study: 32615108
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose of Avapritinib
Study: 32615108
Drug: Recommended phase
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended phase 2 dose of Avapritinib
Study: 32615331
Drug: Nerindocianine sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerindocianine sodium (0.06 mg/kg, 0.12 mg/kg, 0.045 mg/kg)
Study: 32615331
Drug: Nerindocianine sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerindocianine sodium (0.06 mg/kg)
Study: 32615649
Drug: Diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients on insulin
Study: 32615649
Drug: Diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients not on insulin
Study: 32615649
Drug: Non-diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diabetic patients with pre-operative HbA1c < 42 mmol/mol and random plasma glucose < 7.8 mmol/l
Study: 32616009
Drug: Lipid-based Nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based Nutrient Supplement (LNS)
Study: 32616515
Drug: Topical ASN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ASN008 gel
Study: 32616515
Drug: Topical ASN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ASN008 gel (once-daily application for 5 days)
Study: 32616555
Drug: Enzalutamide plus
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide plus pembrolizumab (200 mg IV every 3 weeks for four doses)
Study: 32616557
Drug: Lutathera 3.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutathera 3.7 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Study: 32616557
Drug: Lutathera 7.4
Normalized name: Lutathera 7.4 GBq per 25 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutathera 7.4 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Study: 32616759
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of autologous umbilical cord blood
Study: 32616867
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (three monthly injections followed by PRN regimen)
Study: 32617173
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention designed for psychiatric PTSD patients as a therapy add-on
Study: 32617429
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) targeting sitting balance for 30-45 min daily for 10-12 sessions
Study: 32617429
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) with limited arm movement for 30-45 min daily for 10-12 sessions
Study: 32617435
Drug: Body therapy
Normalized name: Keri Whole Body Therapy Original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body therapy treatment as add-on to treatment as usual
Study: 32617453
Drug: Multistrain probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multistrain probiotic (4 capsules of Vivomixx)
Study: 32617528
Drug: Opt-In Treatment
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opt-In Treatment Approach
Study: 32617528
Drug: Opt-Out Treatment
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opt-Out Treatment Approach
Study: 32617582
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g each, two courses, 2 weeks apart at the beginning and again at 6 months)
Study: 32617919
Drug: ORBERA® Intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORBERA® Intragastric Balloon System (IGB) as an adjunct to lifestyle intervention
Study: 32618884
Drug: empagliflozin 10 mg
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: empagliflozin 10 mg or 25 mg
Study: 32619077
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus letrozole (600 mg for Asian non-Japanese patients; 300 mg for Japanese patients)
Study: 32619077
Drug: Ribociclib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib combined with endocrine therapy
Study: 32619115
Drug: Blinatumomab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab, a CD19 BiTE, administered to adults with MRD BCP-ALL after chemotherapy.
Study: 32622884
Drug: Futibatinib 20
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futibatinib 20 mg q.d.
Study: 32622884
Drug: Futibatinib 8-200
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futibatinib 8-200 mg t.i.w. or 4-24 mg q.d.
Study: 32624195
Drug: Sofosbuvir monotherapy
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir monotherapy
Study: 32624280
Drug: Bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar androgen therapy (BAT) with 400 mg testosterone cypionate intramuscularly every 28 days
Study: 38167882
Drug: Bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar androgen therapy (BAT)
Study: 32624280
Drug: Bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar androgen therapy (BAT) followed by AR-targeted therapy rechallenge
Study: 32627114
Drug: Sirolimus-coated balloon
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-coated balloon (SCB) treatment at the graft vein junction after successful percutaneous thrombectomy.
Study: 32627589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recruitment strategies
Study: 32628583
Drug: Docetaxel given
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel given every 3 weeks for 4 cycles plus subcutaneous trastuzumab
Study: 32628583
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and subcutaneous trastuzumab
Study: 32631491
Drug: UGN-101 (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-101 (mitomycin 4 mg per mL; maximum 60 mg per instillation) administered via retrograde catheter to the renal pelvis and calyces, with six instillations once weekly.
Study: 32631787
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with Aflibercept (Arm A, starting dose 1100 mg/m²)
Study: 32631787
Drug: Capecitabine with
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine with Aflibercept (recommended dose for phase II trials established at 1300 mg/m²)
Study: 32631788
Drug: Panitumumab 6
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg every 2 weeks until progression or unacceptable toxicity
Study: 32633563
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of talimogene laherparepvec with atezolizumab
Study: 32634122
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of IgM and IgG anti-CD4+ cell antibodies
Study: 32634234
Drug: Sonidegib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 400 mg daily + ruxolitinib 20 mg twice daily
Study: 32634238
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of cord donor leukocyte infusion (cDLI) posttransplant.
Study: 32634435
Drug: Histamine-receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-receptor antagonist intake (hazard ratio)
Study: 32634435
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (hazard ratio)
Study: 32634610
Drug: Osimertinib 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 160 mg
Study: 32634611
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression
Study: 32636771
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment for 1 year
Study: 38383268
Drug: Low-pressure hyperbaric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-pressure hyperbaric oxygen therapy (HBOT)
Study: 32637723
Drug: Intensive non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive non-surgical treatment starting with an eight-week low-calorie diet
Study: 34277393
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Chemotherapy (NCT)
Study: 32638247
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of 25(OH)D threshold for maximal suppression of parathyroid hormone (PTH)
Study: 32639484
Drug: Intensive speech
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive speech treatment targeting voice (16 1-hour sessions/1 month)
Study: 32639484
Drug: Intensive speech
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive speech treatment targeting articulation (16 1-hour sessions/1 month)
Study: 32641071
Drug: Patisiran (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (0.3 mg/kg intravenously every 3 weeks)
Study: 32641131
Drug: 0.02% polihexanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% polihexanide solution used for catheter irrigation on five consecutive days
Study: 32641261
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks (Q2W) for ≤ 24 months or until confirmed progression/unacceptable toxicity
Study: 32718906
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks (Q2W)
Study: 32642592
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu (FZHY) tablets and entecavir
Study: 32643995
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (6 infusions over 2 weeks)
Study: 32645016
Drug: Fadraciclib (CYC065)
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadraciclib (CYC065) in combination with BCL2 inhibitors (e.g., venetoclax)
Study: 32645153
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of the renin-angiotensin-aldosterone system
Study: 32645282
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity
Study: 32645640
Drug: Ocrelizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocrelizumab (600 mg treatment cycles at week 0, 24, 48, 72)
Study: 32645640
Drug: Ocrelizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocrelizumab (600 mg treatment cycles)
Study: 32647531
Drug: Apple extract
Normalized name: apple extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple extract (AE, 2.0 g)
Study: 32647531
Drug: Mulberry fruit
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry fruit extract (MFE, 1.5 g)
Study: 32647531
Drug: Mulberry leaf
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry leaf extract (MLE, 1.0 g)
Study: 32647531
Drug: Elderberry extract
Normalized name: elderberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderberry extract (EE, 2.0 g)
Study: 32647531
Drug: Turmeric extract
Normalized name: Turmeric Extract
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric extract (TE, 0.18 g)
Study: 32647531
Drug: White bean
Normalized name: White bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bean extract (WBE, 3.0 g)
Study: 32647531
Drug: Control (rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rice porridge with ~50 g available carbohydrate)
Study: 32647975
Drug: Etelcalcetide (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide (0.035 mg/kg intravenously)
Study: 32648303
Drug: 500-mg ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500-mg ivosidenib in participants with mild hepatic impairment
Study: 32649004
Drug: Neoadjuvant bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant bevacizumab (5 mg/kg) with modified FOLFOX7 (oxaliplatin 85 mg/m2) for six cycles
Study: 32649037
Drug: Supersaturated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supersaturated oxygen (SSO) therapy for 60 minutes